A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

NCT05757102 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

292

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: FF/UMEC/VI
DEVICE: ELLIPTA
DRUG: FF/VI

Sponsor

GlaxoSmithKline